AML

While CLL patients have lived longer with the use of B-cell pathway inhibitors, they require diligent monitoring and even potential suspension to control adverse events.

The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin has been granted breakthrough therapy designation by the FDA as a potential treatment for relapsed or refractory acute lymphoblastic leukemia patients.

John C. Byrd, MD, on Hematologic Malignancies in Chicago about novel agents in treating chronic lymphocytic leukemia, specifically about the emergence of new targeted therapies, including ibrutinib (Imbruvica) and idelalisib (Zydelig) and what clinicians should know about them.

Christoph Roellig, MD, University Hospital Dresden, Dresden, Germany, discusses FLT3 ITD/NPM1 mutation status for patients with AML who are in first remission.

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapse/refractory acute myeloid leukemia (AML).

A new study suggests that the presence of persistent genetic mutations, 30 days after induction chemotherapy, predicted relapse and survival in patients with acute myeloid leukemia (AML), as well as intermediate-risk patients.

Venetoclax (ABT-199) monotherapy showed promising phase II results, which will be submitted to regulatory agencies for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion.

Jeffrey Jones, MD, MPH, assistant professor, Internal Medicine, section head, Chronic Lymphocytic Leukemia (CLL) research program, Ohio State University, discusses idelalisib (Zydelig) for previously treated CLL.

This review addresses the basics of CAR T-cell design and reviews data from published clinical studies in leukemia.

CPX-351 demonstrated a complete response (CR) or CR with incomplete hematologic recovery rate of 47.7% in elderly patients with untreated secondary acute myeloid leukemia.

Treatment with ibrutinib plus the anti-CD20 antibody ublituximab was shown to be safe with an objective response rate of 95% in patients with chronic lymphocytic leukemia.

Treatment with inotuzumab ozogamicin was found to be safe and effective in a phase III study for patients with relapsed or refractory acute lymphoblastic leukemia.

The IDH2 inhibitor AG-221 has demonstrated promising response rates in patients with acute myeloid leukemia and other hematologic malignancies.

The combination of ibrutinib with bendamustin plus rituximab (BR) demonstrated a significant improvement in progression-free survival compared with BR alone in patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

The chimeric antigen receptor (CAR) T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

Cytogenetic and molecular data are becoming increasingly important in the individualization of treatment of patients with acute myeloid leukemia (AML).

Experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

The FDA has granted a Fast Track Designation to CPX-351, a liposomal formulation of cytarabine and daunorubicin, for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).

Bayard L. Powell, MD, discusses a phase I study that looked at CPI-613 in combination with high dose ARA-C and mitoxantrone for the treatment of patents with relapsed/refractory acute myeloid leukemia (AML).

Treatment with the tyrosine kinase inhibitor (TKI) sorafenib in combination with standard chemotherapy increased event-free survival (EFS) by 11.3 months in patients with newly diagnosed AML.

In a phase II trial, some patients with heavily treated acute myelogenous leukemia (AML) benefited from treatment with the BCL-2 inhibitor venetoclax (ABT-199).

Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses CAR T-cell therapy for the treatment of acute lymphoblastic leukemia.

The novel drug AG-221 generated durable remissions in patients with acute myeloid leukemia (AML) by targeting a mutation of the IDH2 gene in a small, first-in-man study that represents a new, chemotherapy-free approach for attacking the malignancy. Eytan M. Stein, MD, reported these findings during a press briefing at the 56th Annual Meeting of the American Society of Hematology (ASH).

The anti-CD19 immunotherapy blinatumomab (Blincyto) has been approved by the FDA as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), based on findings from a phase II trial.

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.